BeiGene, Ltd. (NASDAQ:BGNE) Insider Sells $1,101,750.00 in Stock

BeiGene, Ltd. (NASDAQ:BGNE) insider Lai Wang sold 5,000 shares of the company’s stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $220.35, for a total value of $1,101,750.00. Following the completion of the sale, the insider now directly owns 920,920 shares of the company’s stock, valued at $202,924,722. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

BeiGene Stock Up 0.0 %

NASDAQ:BGNE opened at $233.64 on Friday. The stock has a 50-day simple moving average of $193.54 and a 200 day simple moving average of $167.83. BeiGene, Ltd. has a 52-week low of $126.97 and a 52-week high of $238.80. The company has a market cap of $22.64 billion, a PE ratio of -30.86 and a beta of 0.61. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, topping the consensus estimate of ($2.27) by $1.12. BeiGene had a negative net margin of 16.91% and a negative return on equity of 14.93%. The company had revenue of $929.20 million during the quarter, compared to analysts’ expectations of $810.34 million. During the same period last year, the business earned ($3.64) EPS. The business’s quarterly revenue was up 56.1% on a year-over-year basis. On average, sell-side analysts expect that BeiGene, Ltd. will post -5.13 EPS for the current fiscal year.

Analyst Ratings Changes

BGNE has been the subject of several recent analyst reports. Bank of America lowered their target price on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a research note on Tuesday, July 9th. JPMorgan Chase & Co. upped their price objective on shares of BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. JMP Securities initiated coverage on BeiGene in a report on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 target price on the stock. Finally, Citigroup increased their price target on BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $241.21.

Institutional Investors Weigh In On BeiGene

Several institutional investors and hedge funds have recently added to or reduced their stakes in BGNE. Headlands Technologies LLC bought a new position in shares of BeiGene in the 1st quarter valued at about $50,000. SG Americas Securities LLC bought a new position in BeiGene in the third quarter valued at approximately $105,000. Benjamin F. Edwards & Company Inc. increased its position in shares of BeiGene by 51.5% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 821 shares of the company’s stock worth $128,000 after purchasing an additional 279 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of BeiGene by 204.1% during the 1st quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock worth $197,000 after purchasing an additional 849 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. bought a new stake in shares of BeiGene during the 1st quarter worth approximately $209,000. 48.55% of the stock is owned by institutional investors.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.